Belt and Road Summit 2025- Deal-making

10–16 Sept 2025 | China (Hong Kong)

ProjectUpdated on 10 September 2025

Westelite - Biotech Skincare

LU XU

Founder at Westelite Capital

Hangzhou, China

About

Westelite leveraged its investment experience to incubate technology-based enterprises, establishing a precision synthetic biology technology platform. This initiative defined a raw material technology roadmap centered on Bio-Activated Oil and established a core product strategy: "Skin care through technology, nourishing skin with oils."

Centered around this strategy, we have deepened our supply chain capabilities, driving innovation and optimization in raw material technology. Collaborating with our team, we have refined high-standard skincare formulations. Through precise brand positioning and rigorous product development, we successfully launched four star products under the "WESTELiTE" brand: Camellia Japonica Revitalizing Serum Oil, Camellia Japonica Anti-aging Cream, Camellia Japonica Eye Serum Oil, and Camellia Japonica Eye Cream. These products integrate cutting-edge synthetic biology technology, delivering exceptional benefits in deep nourishment, repair, and skin condition enhancement. Their lightweight, luxurious texture has earned consumer trust through an indulgent application experience.

Project Location

  • China

Project Format

  • Private Project

ESG (Environmental, Social, and Governance)

  • No

Project Stage

  • Operations

Main Project Sector

  • Technology

Technology

  • Bio-Tech

Total Project Value

  • 500,001 to 1,000,000 USD

Investment Capital Required

  • 500,001 to 1,000,000 USD

Interested Format of Cooperation

  • Minority Shareholdings

Preferred Financing Model

  • Open for negotiation

Previous Funding Stage

  • None

Main Service(s) Required

  • Information Technology Services
  • Transportation Services

Information Technology Services

  • E-commerce
  • Import & Export Solutions

Organisation

Westelite Capital

Hangzhou, China

Similar opportunities

  • Project

    Estelle Biovita

    • No
    • None
    • Bio-Tech
    • Technology
    • Joint Venture
    • R&D Cooperation
    • Project Planning
    • Health Technology
    • Financial Services
    • 500,000 USD or Below
    • Open for Negotiation
    • Open for negotiation
    • Professional Services
    • 1,000,001 to 2,500,000 USD
    • Public-Private Partnership Project

    Daisy Tan

    Business Development Officer at InnoHK Centre for Translational Stem Cell Biology

    Hong Kong, China (Hong Kong)

  • Project

    COLLABORATION; CAR BRANDS, SECURITY CAMERA BRANDS, SMARTPHONE BRANDS

    • No
    • IoT
    • IoT
    • None
    • Operations
    • Technology
    • Public Project
    • R&D Cooperation
    • Open for Negotiation
    • Open for negotiation
    • Smart City Development
    • 50,000,001 USD or above
    • 500,001 to 1,000,000 USD
    • Information Technology Services
    • Public–private partnership / Concession

    Tim Lui

    founder at iii Hong Kong Limited

    hong kong, China (Hong Kong)

  • Project

    APAC Lead

    • Yes
    • None
    • Manufacturing
    • Private Project
    • Financial Services
    • 50,000,001 USD or above
    • 500,001 to 1,000,000 USD
    • Feasibility Study Completed

    Dongliang Ye

    APAC Lead at Meacheal

    Hangzhou, China